Patents by Inventor Paul Goodfellow

Paul Goodfellow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190094229
    Abstract: Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.
    Type: Application
    Filed: December 7, 2018
    Publication date: March 28, 2019
    Inventors: Pamela Pollock, Paul Goodfellow
  • Patent number: 10191057
    Abstract: Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: January 29, 2019
    Assignees: The Translational Genomics Research Institute, Washington University
    Inventors: Pamela Pollock, Paul Goodfellow
  • Publication number: 20160209417
    Abstract: Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.
    Type: Application
    Filed: March 31, 2016
    Publication date: July 21, 2016
    Inventors: Pamela Pollock, Paul Goodfellow
  • Publication number: 20140234841
    Abstract: In one aspect, the disclosure provides isolated nucleic acids, polypeptides, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicants: Children's Hospital and Clinics of Minnesota, The Washington University in St. Louis
    Inventors: Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger
  • Publication number: 20140057261
    Abstract: Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Pamela Pollock, Paul Goodfellow
  • Publication number: 20120040357
    Abstract: In one aspect, the disclosure provides isolated nucleic acids, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.
    Type: Application
    Filed: December 18, 2009
    Publication date: February 16, 2012
    Applicants: THE WASHINGTON UNIVERSITY IN SAINT LOUIS, CHILDREN'S HOSPITAL AND CLINICS OF MINNESOTA
    Inventors: Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger
  • Publication number: 20100111944
    Abstract: Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.
    Type: Application
    Filed: March 24, 2008
    Publication date: May 6, 2010
    Applicant: Washington University
    Inventors: Pamela Pollock, Paul Goodfellow